gsk201306186k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending June 2013
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Issued: Tuesday 18 June 2013, London UK
GSK receives offer for its thrombosis brands and related manufacturing site
GlaxoSmithKline (LSE: GSK) has today received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited. A period of exclusivity has been agreed with Aspen and GSK will respond to the offer subject to consultation with employees and the relevant works councils.
The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra® and Fraxiparine® (excluding China, India and Pakistan) brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees.
The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline.
V A Whyte
Company Secretary
18 June 2013
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
|
GlaxoSmithKline Enquiries:
|
|
|
|
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
| |
David Daley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
Catherine Hartley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
|
|
|
|
US Media enquiries:
|
Stephen Rea
|
+1 215 751 4394
|
(Philadelphia)
|
| |
Kevin Colgan
|
+1 919 483 2933
|
(North Carolina)
|
| |
Melinda Stubbee
|
+1 919 483 2510
|
(North Carolina)
|
| |
Mary Anne Rhyne
|
+1 919 483 0492
|
(North Carolina)
|
| |
Sarah Alspach
|
+1 202 715 1048
|
(Washington, DC)
|
| |
Jennifer Armstrong
|
+1 215 751 5664
|
(Philadelphia)
|
| |
|
|
|
|
Analyst/Investor enquiries:
|
Ziba Shamsi
|
+ 44 (0) 20 8047 3289
|
(London)
|
| |
Lucy Budd
|
+44 (0) 20 8047 2248
|
(London)
|
| |
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
| |
Gary Davies
|
+ 44 (0) 20 8047 5503
|
(London)
|
| |
James Dodwell
|
+ 44 (0) 20 8047 2406
|
(London)
|
| |
Jeff McLaughlin
|
+ 1 215 751 7002
|
(Philadelphia)
|
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.
|
|
Registered in England & Wales:
No. 3888792
|
| |
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: June 18, 2013
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc